Dr. Monica Yamile Ovalle Abuabara, M.D General Practice Medicare: Not Enrolled in Medicare Practice Location: 1300 State St, Suite 2 F, La Porte, IN 46350 Phone: 219-326-8883 Fax: 219-326-8882 |
News Archive
Great hopes are always placed in new cancer therapies. However, whether new surgical techniques, drugs or radiation therapies actually prolong the life of cancer patients, or even cure them, can often only be reliably assessed after several years' of testing. Researchers are therefore looking for proxy markers that after initiation of cancer therapy can reliably predict as quickly as possible whether the treatment has a benefit.
Today, Ronald McDonald House Charities of Southern California (RMHCSC) awarded $328,000 in scholarship funds to exceptional high school seniors who reside in Los Angeles, Orange, Riverside, San Bernardino and Ventura counties.
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.
"Is There a Downside to Shooting for the Stars? Unrealized Educational Expectations and Symptoms of Depression," which was published in the American Sociological Review (http://asr.sagepub.com/cgi/content/full/75/1/151), is the first large, national study to look at the mental health consequences of failing to meet educational expectations.
Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
› Verified 9 days ago